See more : KKR & Co. Inc. (KKR) Income Statement Analysis – Financial Results
Complete financial analysis of The Macerich Company (MAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Macerich Company, a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- Investeringsforeningen Investin – I&T Nordiske Aktier Large Cap (INIITNAKTLC.CO) Income Statement Analysis – Financial Results
- Enterprise Financial Services Corp (EFSC) Income Statement Analysis – Financial Results
- Doré Copper Mining Corp. (DRCMF) Income Statement Analysis – Financial Results
- Prakash Woollen & Synthetic Mills Limited (PWASML.BO) Income Statement Analysis – Financial Results
- Bangkok Dusit Medical Services Public Company Limited (BDUUF) Income Statement Analysis – Financial Results
The Macerich Company (MAC)
About The Macerich Company
Macerich is a fully integrated, self-managed and self-administered real estate investment trust, which focuses on the acquisition, leasing, management, development and redevelopment of regional malls throughout the United States. Macerich currently owns 51 million square feet of real estate consisting primarily of interests in 47 regional shopping centers. Macerich specializes in successful retail properties in many of the country's most attractive, densely populated markets with significant presence in the West Coast, Arizona, Chicago and the Metro New York to Washington, DC corridor. A recognized leader in sustainability, Macerich has achieved the #1 GRESB ranking in the North American Retail Sector for five straight years (2015 - 2019).
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 881.37M | 859.16M | 847.44M | 786.03M | 927.46M | 960.35M | 993.66M | 1.04B | 1.29B | 1.11B | 1.03B | 881.32M | 791.25M | 758.56M | 805.65M | 439.85M | 896.37M | 829.66M | 767.39M | 547.27M | 486.00M | 378.92M | 334.57M | 320.09M | 327.44M | 283.86M | 221.21M | 155.06M | 105.70M | 74.50M |
| Cost of Revenue | 394.89M | 390.35M | 380.88M | 347.98M | 367.95M | 381.00M | 395.31M | 405.95M | 472.16M | 441.93M | 423.26M | 366.14M | 342.40M | 336.29M | 337.48M | 364.15M | 73.76M | 99.49M | 52.84M | 38.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 486.48M | 468.81M | 466.55M | 438.05M | 559.51M | 579.35M | 598.35M | 635.33M | 815.99M | 663.32M | 606.22M | 515.18M | 448.85M | 422.27M | 468.18M | 75.70M | 822.61M | 730.16M | 714.55M | 508.97M | 486.00M | 378.92M | 334.57M | 320.09M | 327.44M | 283.86M | 221.21M | 155.06M | 105.70M | 74.50M |
| Gross Profit Ratio | 55.20% | 54.57% | 55.05% | 55.73% | 60.33% | 60.33% | 60.22% | 61.01% | 63.35% | 60.02% | 58.89% | 58.46% | 56.73% | 55.67% | 58.11% | 17.21% | 91.77% | 88.01% | 93.11% | 93.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | -0.08 | -0.06 | 0.16 | 0.21 | 0.12 | 0.14 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 29.24M | 27.16M | 30.06M | 30.34M | 22.63M | 24.16M | 28.24M | 28.22M | 29.87M | 29.41M | 27.77M | 20.41M | 21.11M | 20.70M | 25.93M | 16.52M | 16.60M | 13.53M | 12.11M | 11.08M | 10.72M | 8.27M | 6.78M | 5.51M | 5.49M | 4.37M | 2.76M | 2.38M | 2.00M | 1.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.24M | 27.16M | 30.06M | 30.34M | 22.63M | 24.16M | 28.24M | 28.22M | 29.87M | 29.41M | 27.77M | 20.41M | 21.11M | 20.70M | 25.93M | 16.52M | 16.60M | 13.53M | 12.11M | 11.08M | 10.72M | 8.27M | 6.78M | 5.51M | 5.49M | 4.37M | 2.76M | 2.38M | 2.00M | 1.50M |
| Other Expenses | 0.00 | 291.61M | 311.13M | 319.62M | 330.73M | 346.81M | -13.63M | -13.38M | 10.29M | 1.41B | -35.72M | 198.15M | 265.33M | 246.81M | 262.06M | 277.83M | 594.69M | 543.07M | 502.69M | 345.38M | 280.38M | 208.16M | 176.81M | 163.32M | 161.71M | 143.13M | 112.44M | 50.79M | 0.00 | 0.00 |
| Operating Expenses | 489.18M | 318.78M | 341.19M | 349.96M | 353.36M | 370.97M | 363.67M | 376.71M | 494.34M | 408.13M | 384.94M | 322.97M | 286.44M | 267.52M | 283.24M | 350.40M | 611.29M | 556.61M | 514.80M | 356.45M | 291.10M | 216.43M | 183.59M | 168.83M | 167.20M | 147.51M | 115.20M | 53.17M | -57.30M | -41.40M |
| Cost & Expenses | 668.67M | 709.13M | 722.07M | 697.94M | 721.31M | 751.97M | 758.98M | 782.65M | 966.50M | 850.06M | 808.19M | 689.11M | 628.85M | 603.81M | 620.71M | 350.40M | 611.29M | 556.61M | 514.80M | 356.45M | 291.10M | 216.43M | 183.59M | 168.83M | 167.20M | 147.51M | 115.20M | 53.17M | -57.30M | -41.40M |
| Interest Income | 0.00 | 216.85M | 192.68M | 75.55M | 138.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 172.92M | 216.85M | 192.68M | 75.55M | 138.25M | 182.96M | 171.78M | 163.68M | 211.94M | 190.69M | 197.25M | 176.78M | 195.29M | 212.82M | 267.05M | 281.36M | 250.13M | 0.00 | 249.91M | 146.33M | 132.51M | 122.93M | 109.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 296.39M | 732.71M | 731.07M | 558.42M | 644.67M | 736.74M | 758.98M | 782.65M | 464.47M | 378.72M | 357.17M | 302.55M | 282.64M | 260.25M | 262.06M | 96.44M | 243.10M | 236.67M | 208.93M | 146.38M | 109.03M | 78.84M | 65.98M | 61.65M | 61.38M | 53.14M | 41.54M | 32.59M | 26.30M | 19.20M |
| EBITDA | 190.72M | 436.39M | 452.19M | 155.70M | 585.38M | 583.01M | 570.11M | 864.76M | 987.38M | 1.99B | 597.56M | 514.94M | 445.05M | 415.00M | 277.47M | 228.57M | 243.23M | 484.22M | 461.52M | 331.73M | 260.72M | 209.90M | 162.71M | 212.91M | 221.63M | 189.50M | 147.55M | 134.48M | 189.30M | 135.10M |
| EBITDA Ratio | 21.64% | 50.79% | 53.36% | 27.65% | 63.12% | 63.27% | 64.61% | 62.49% | 65.33% | 190.74% | 69.00% | 87.62% | 93.49% | 68.59% | 31.76% | 42.26% | 59.02% | 61.44% | 60.14% | 61.44% | 59.98% | 64.70% | 57.53% | 66.51% | 67.68% | 66.76% | 66.70% | 86.73% | 179.09% | 181.34% |
| Operating Income | 149.92M | 144.78M | 141.06M | -102.25M | 254.66M | 208.38M | 234.68M | 258.62M | 321.65M | 255.19M | 221.28M | 192.22M | 162.40M | 154.75M | 180.18M | 242.99M | 285.08M | 273.05M | 252.59M | 190.81M | 194.90M | 162.49M | 150.98M | 151.26M | 160.25M | 136.36M | 106.02M | 101.89M | 163.00M | 115.90M |
| Operating Income Ratio | 17.01% | 16.85% | 16.65% | -13.01% | 27.46% | 21.70% | 23.62% | 24.84% | 24.97% | 23.09% | 21.49% | 21.81% | 20.52% | 20.40% | 22.36% | 55.25% | 31.80% | 32.91% | 32.92% | 34.87% | 40.10% | 42.88% | 45.13% | 47.26% | 48.94% | 48.04% | 47.93% | 65.71% | 154.21% | 155.57% |
| Total Other Income/Expenses | -423.49M | -216.81M | -102.26M | -334.00M | -102.01M | -143.01M | -57.41M | 296.94M | 198.04M | 1.35B | -63.95M | 106.79M | 70.93M | -120.55M | -527.00K | -148.01M | -157.40M | -194.08M | -158.14M | -81.02M | -36.80M | -50.75M | -170.31M | -94.33M | 0.00 | 0.00 | 0.00 | 0.00 | -163.00M | 0.00 |
| Income Before Tax | -273.57M | -64.37M | 23.11M | -245.91M | 104.14M | 65.37M | 177.27M | 555.56M | 519.69M | 1.60B | 157.33M | 292.87M | 203.12M | 37.83M | 170.13M | 149.00M | 110.35M | 252.33M | 71.69M | 91.63M | 128.03M | 81.38M | 77.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -31.04% | -7.49% | 2.73% | -31.29% | 11.23% | 6.81% | 17.84% | 53.35% | 40.34% | 145.00% | 15.28% | 33.23% | 25.67% | 4.99% | 21.12% | 33.87% | 12.31% | 30.41% | 9.34% | 16.74% | 26.34% | 21.48% | 23.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -494.00K | 705.00K | 6.95M | -447.00K | 1.59M | -3.60M | 15.59M | 722.00K | -3.22M | -4.27M | -1.69M | -4.16M | -6.11M | 9.20M | -4.76M | 1.13M | -470.00K | -33.00K | 171.95M | 99.18M | 66.87M | 81.11M | 73.26M | 94.33M | 31.24M | 92.28M | 83.97M | 82.98M | 151.70M | 107.30M |
| Net Income | -274.07M | -65.08M | 14.26M | -245.46M | 96.82M | 60.02M | 146.13M | 517.00M | 487.56M | 1.50B | 420.09M | 337.43M | 156.87M | 25.19M | 120.74M | 93.83M | 96.54M | 252.36M | 71.69M | 91.63M | 128.03M | 81.38M | 77.72M | 56.93M | 129.01M | 44.08M | 22.05M | 18.91M | 11.30M | 8.60M |
| Net Income Ratio | -31.10% | -7.57% | 1.68% | -31.23% | 10.44% | 6.25% | 14.71% | 49.65% | 37.85% | 135.63% | 40.81% | 38.29% | 19.83% | 3.32% | 14.99% | 21.33% | 10.77% | 30.42% | 9.34% | 16.74% | 26.34% | 21.48% | 23.23% | 17.79% | 39.40% | 15.53% | 9.97% | 12.20% | 10.69% | 11.54% |
| EPS | -1.28 | -0.30 | 0.07 | -1.68 | 0.76 | 0.43 | 1.04 | 3.59 | 3.16 | 9.48 | 159.02K | 2.45 | 1.18 | 0.19 | 1.45 | 1.19 | 0.99 | 3.10 | 0.86 | 1.36 | 2.03 | 1.57 | 1.66 | 1.07 | 3.14 | 1.02 | 0.82 | 0.88 | 0.70 | 0.58 |
| EPS Diluted | -1.28 | -0.30 | 0.07 | -1.68 | 0.76 | 0.43 | 1.04 | 3.59 | 3.16 | 9.48 | 159.02K | 2.45 | 1.18 | 0.19 | 1.45 | 1.19 | 0.98 | 3.07 | 0.85 | 1.35 | 2.01 | 1.56 | 1.66 | 1.07 | 2.88 | 1.02 | 0.82 | 0.86 | 0.70 | 0.58 |
| Weighted Avg Shares Out | 215.55M | 215.03M | 198.07M | 146.23M | 141.34M | 141.14M | 140.99M | 143.99M | 154.40M | 158.20M | 139.60M | 134.07M | 131.63M | 120.35M | 81.23M | 76.49M | 74.50M | 73.52M | 61.54M | 60.73M | 55.70M | 38.83M | 35.03M | 35.51M | 35.30M | 31.98M | 26.88M | 21.57M | 16.07M | 14.88M |
| Weighted Avg Shares Out (Dil) | 215.55M | 215.03M | 198.07M | 146.23M | 141.34M | 141.22M | 140.99M | 143.99M | 154.40M | 158.20M | 140.73M | 137.51M | 131.63M | 120.35M | 81.23M | 89.77M | 87.99M | 91.41M | 76.37M | 61.17M | 56.23M | 39.07M | 35.03M | 35.51M | 63.21M | 45.29M | 39.86M | 21.97M | 16.07M | 14.88M |
Macerich Declares the Quarterly Dividend on Its Common Shares
SANTA MONICA, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of the Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $.17 per share of common stock. The dividend is payable on December 2, 2024, to...
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of...
Macerich Refinances Top-Performing Queens Center at Favorable Terms
5.37% Fixed Rate for 5 Years, Interest Only, on $525M Loan Lowest Refi Rate Achieved by Company in Past 5 Years SANTA MONICA, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Macerich (NYSE: MAC), one of the nation's leading owners, operators...
Macerich: Old Retail Is Fading
Macerich is a REIT focused on malls and shopping centers, currently yielding 3.8%, with no clear growth story. Management aims to reduce debt by $2B through asset sales, but this likely means revenue and cash flows will decline in the...
Macerich Schedules Third Quarter 2024 Earnings Release and Conference Call
SANTA MONICA, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- WHAT: Macerich (NYSE: MAC) Schedules Third Quarter 2024 Earnings Release and Conference Call
Is it Wise to Retain Macerich Stock in Your Portfolio Now?
A portfolio of premium shopping centers, focus on omnichannel retailing and developing mixed-use assets, will likely aid MAC despite growing e-commerce adoption.
Why Is Macerich (MAC) Up 0.8% Since Last Earnings Report?
Macerich (MAC) reported earnings 30 days ago. What's next for the stock?
What I Wish I Knew Before Buying REITs
REITs are proven long-term wealth compounders with the benefits of real estate investing, economies of scale, and diversification. However, there are several important aspects of REIT investing that many investors fail to take into account. We discuss four key lessons...
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3...
Source: https://incomestatements.info
Category: Stock Reports